Northern Trust’s 10x Genomics TXG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$103M Sell
1,137,811
-6,216
-0.5% -$364K 0.01% 740
2026
Q2
$43.9M Buy
1,144,027
+96,022
+9% +$2.52M 0.01% 1286
2026
Q1
$22.2M Buy
1,048,005
+54,625
+5% +$1.09M ﹤0.01% 1610
2025
Q4
$16.2M Sell
993,380
-45,883
-4% -$693K ﹤0.01% 1807
2025
Q3
$12.1M Buy
1,039,263
+29,951
+3% +$391K ﹤0.01% 2004
2025
Q2
$11.7M Buy
1,009,312
+460,280
+84% +$4.2M ﹤0.01% 1972
2025
Q1
$4.79M Sell
549,032
-12,634
-2% -$159K ﹤0.01% 2425
2024
Q4
$8.07M Sell
561,666
-31,923
-5% -$504K ﹤0.01% 2245
2024
Q3
$13.4M Sell
593,589
-55,221
-9% -$1.14M ﹤0.01% 1889
2024
Q2
$12.6M Buy
648,810
+56,948
+10% +$1.49M ﹤0.01% 1855
2024
Q1
$22.2M Buy
591,862
+122,227
+26% +$5.37M ﹤0.01% 1518
2023
Q4
$26.3M Sell
469,635
-2,450
-0.5% -$107K ﹤0.01% 1423
2023
Q3
$19.5M Buy
472,085
+11,599
+3% +$603K ﹤0.01% 1561
2023
Q2
$25.7M Buy
460,486
+3,835
+0.8% +$208K ﹤0.01% 1421
2023
Q1
$25.5M Buy
456,651
+58,937
+15% +$2.75M 0.01% 1395
2022
Q4
$14.5M Buy
397,714
+4,779
+1% +$156K ﹤0.01% 1760
2022
Q3
$11.2M Buy
392,935
+6,341
+2% +$242K ﹤0.01% 1897
2022
Q2
$17.5M Sell
386,594
-88,125
-19% -$4.57M ﹤0.01% 1623
2022
Q1
$36.1M Buy
474,719
+5,285
+1% +$462K 0.01% 1265
2021
Q4
$69.9M Sell
469,434
-50,359
-10% -$7.71M 0.01% 868
2021
Q3
$75.7M Buy
519,793
+42,144
+9% +$7.24M 0.01% 806
2021
Q2
$93.5M Buy
477,649
+68,786
+17% +$12.4M 0.02% 707
2021
Q1
$74M Buy
408,863
+13,132
+3% +$2.27M 0.01% 834
2020
Q4
$56M Buy
395,731
+107,242
+37% +$15.6M 0.01% 984
2020
Q3
$36M Buy
288,489
+105,361
+58% +$11.1M 0.01% 1145
2020
Q2
$16.4M Buy
183,128
+158,666
+649% +$12.4M ﹤0.01% 1777
2020
Q1
$1.52M Buy
24,462
+1,777
+8% +$139K ﹤0.01% 3004
2019
Q4
$1.73M Buy
22,685
+14,471
+176% +$870K ﹤0.01% 3205
2019
Q3
$414K Buy
+8,214
New +$455K ﹤0.01% 3587

Other funds holding TXG

Northern Trust's TXG Position: Q3 2026 in Review

Northern Trust reduced its 10x Genomics (TXG) stake by 0.54% in Q3 2026, selling an estimated $364K and leaving 1,137,811 shares worth $103M. The position accounts for 0.01% of the portfolio, ranked #740.

Northern Trust first reported a position in TXG in Q3 2019 and has held it in 29 quarters since. 491 funds tracked by Wall St. Rank hold TXG as of Q3 2026.

  • Northern Trust held 1,137,811 shares of 10x Genomics worth $103M as of Q3 2026.
  • Northern Trust sold 6,216 10x Genomics shares in Q3 2026, an estimated $364K.
  • 10x Genomics made up 0.01% of Northern Trust's portfolio in Q3 2026, its #740 holding.
  • Northern Trust first reported a position in 10x Genomics in Q3 2019 and has held it in 29 quarters since.
  • 491 funds tracked by Wall St. Rank held 10x Genomics as of Q3 2026.

Based on Northern Trust's 13F filing for Q3 2026, filed 16 Nov 2026.